<DOC>
	<DOC>NCT01797185</DOC>
	<brief_summary>Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis</brief_summary>
	<brief_title>An Open Label and Safety Study of the Safety Of SPARC1104</brief_title>
	<detailed_description>Safety study of SPARC1104</detailed_description>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Willingness to participate and give written informed consent Men and women â‰¥ 18 years of age Sexually active women who are of child bearing potential will practice an acceptable method of birth control for the duration of the trial as judged by the investigator. Examples of acceptable contraception are: condoms, foams, jellies, diaphragm, intrauterine device, oral or longacting injected contraceptives, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or having a partner who is incapable of initiating conception. The practice of contraception must have started at least 3 months prior to trial entry. If female, negative pregnancy test result at Screening Diagnosed with MS and a known history of spasticity Meet one of the following criteria Subjects who completed the doubleblind randomized withdrawal phase (Part 3) of trial CLR_09_21 with no major protocol violation Subjects who are newly diagnosed with spasticity due to MS with no history of treatment using any antispasticity medications, or, with a history of spasticity due to MS but with no previous exposure to baclofen treatment Subjects who are receiving a stable baclofen IR dose (ie, a dose of 10 mg to 80 mg daily, having started at least 30 days prior to enrollment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>baclofen, spasticity</keyword>
</DOC>